UPDATE: Citigroup Upgrades Edwards Lifesciences on Upcoming Catalysts, Attractive Risk/Reward
October 16, 2013 at 10:23 AM EDT
In a report published Wednesday, Citigroup analyst Amit Bhalla upgraded the rating on Edwards Lifesciences Corp. (NYSE: EW ) from Neutral to Buy, and raised the price target from $75.00 to $86.00. In the report, Citigroup noted, “We are upgrading EW to Buy (from a Neutral) and are increasing our
